XClose

UCL Design Language

Home

A nascent retina, generated from a 3D embryonic stem cell culture

Menu
Contents
Metadata
Published
Display
per page
Located
km
Within

41 - 50 of 108 search results for !padrenullquery -UclCommunicationType:"announcement" UclOrgUnit:"cancer institute"

Results

  1. Exploring the secrets of DNA with GenoME | UCL Cancer Institute - UCL …

    https://www.ucl.ac.uk/cancer/news/2018/apr/exploring-secrets-dna-genome

    13 Apr 2018: Last night, at a special launch event held at UCL, the Personal Genome Project UK celebrated the completion of the PGP-UK pilot study and unveiled ‘GenoME’ - a free educational app designed to explore personal genetic code.

    Last night, at a special launch event held at UCL, the Personal Genome Project UK celebrated the completion of the PGP-UK pilot study and unveiled ‘GenoME’ - a free educational app designed to explore personal genetic code.

  2. 2018 | UCL Cancer Institute - UCL – University College London

    https://www.ucl.ac.uk/cancer/news/2018

    12 Apr 2018:

  3. Prostate MRI scans increase cancer detection & reduce…

    https://www.ucl.ac.uk/cancer/news/2018/prostate-cancer-mri-biopsy

    19 Mar 2018: A large international study led by UCL and UCLH researchers, has found that an MRI scan and targeted prostate biopsies, are significantly better at making a positive prostate cancer diagnosis than standard biopsies.

    A large international study led by UCL and UCLH researchers, has found that an MRI scan and targeted prostate biopsies, are significantly better at making a positive prostate cancer diagnosis than standard biopsies.

  4. UCL cancer trials to get £9m funding boost | UCL Cancer Institute -…

    https://www.ucl.ac.uk/cancer/news/2018/cruk-ucl-cancer-trials-centre-funding-award-2018

    15 Feb 2018: Cancer Research UK is planning to invest nearly £9m over the next five years into research at the Cancer Research UK & UCL Cancer Trials Centre. The announcement is part of a £45 million investment into Cancer Research UK’s network of clinical

    Cancer Research UK is planning to invest nearly £9m over the next five years into research at the Cancer Research UK & UCL Cancer Trials Centre. The announcement is part of a £45 million investment into Cancer Research UK’s network of clinical

  5. UCL awarded £1m for major research project on rare cancer | UCL…

    https://www.ucl.ac.uk/cancer/news/2018/tom-prince-trust-donation-osteosarcoma-project

    14 Feb 2018: A UK wide research network for osteosarcoma, a rare type of bone cancer primarily affecting teenagers and young adults, is to be set up by UCL, led by Professor Adrienne Flanagan, thanks to a generous gift of £1m from The Tom Prince Cancer Trust.

    A UK wide research network for osteosarcoma, a rare type of bone cancer primarily affecting teenagers and young adults, is to be set up by UCL, led by Professor Adrienne Flanagan, thanks to a generous gift of £1m from The Tom Prince Cancer Trust.

  6. One cigarette a day increases cardiovascular risk | UCL Cancer…

    https://www.ucl.ac.uk/cancer/news/2018/no-safe-level-of-smoking

    25 Jan 2018: Smoking just one cigarette a day carries a much higher risk of developing coronary heart disease and stroke than expected – about half the risk of smoking 20 per day – concludes a new study published in the BMJ today.

    Smoking just one cigarette a day carries a much higher risk of developing coronary heart disease and stroke than expected – about half the risk of smoking 20 per day – concludes a new study published in the BMJ today.

  7. New ovarian cancer drug based on UCL research | UCL Cancer Institute…

    https://www.ucl.ac.uk/cancer/news/2018/jan/new-ovarian-cancer-drug-based-ucl-research

    2 Jan 2018: A new drug to delay the spread of ovarian cancer, which was developed from UCL research, has been licensed for use in the UK. Professor Jonathan Ledermann, who led the research, said the drug was a “critical milestone” in managing the disease if

    A new drug to delay the spread of ovarian cancer, which was developed from UCL research, has been licensed for use in the UK. Professor Jonathan Ledermann, who led the research, said the drug was a “critical milestone” in managing the disease if

  8. Immunotherapy discovery a step towards treating T cell cancers | UCL…

    https://www.ucl.ac.uk/cancer/news/2018/jan/immunotherapy-discovery-step-towards-treating-t-cell-cancers

    2 Jan 2018: Researchers have discovered a new way of potentially treating mature T cell cancers using immunotherapy. The study, published in Nature Medicine, demonstrates how chimeric antigen receptor (CAR) T cells can be used to selectively target cancerous T

    Researchers have discovered a new way of potentially treating mature T cell cancers using immunotherapy. The study, published in Nature Medicine, demonstrates how chimeric antigen receptor (CAR) T cells can be used to selectively target cancerous T

  9. Tumour Heterogeneity Team wins Cancer Research UK Translational…

    https://www.ucl.ac.uk/cancer/news/tumour-heterogeneity-team-win-cruk-translational-cancer-research-prize-2017

    11 Dec 2017: The Tumour Heterogeneity Team, led by Professor Charles Swanton, has been awarded the Cancer Research UK Translational Research Prize at the National Cancer Research Institute (NCRI) conference 2017.

    The Tumour Heterogeneity Team, led by Professor Charles Swanton, has been awarded the Cancer Research UK Translational Research Prize at the National Cancer Research Institute (NCRI) conference 2017.

  10. Osimertinib shows promise as new standard-of-care treatment for…

    https://www.ucl.ac.uk/cancer/news/2017/dec/osimertinib-shows-promise-new-standard-care-treatment-advanced-lung-cancer

    11 Dec 2017: Positive results from the phase-three FLAURA clinical trial show significant improvement in progression free survival in patients with EGFR-mutated advanced non-small cell lung cancer treated with Osimertinib, compared to patients treated with

    Positive results from the phase-three FLAURA clinical trial show significant improvement in progression free survival in patients with EGFR-mutated advanced non-small cell lung cancer treated with Osimertinib, compared to patients treated with

Pagination

Refine

Subjects

Organisational Units

Communication types

Audiences